AKR1C3 as a target in castrate resistant prostate cancer

- Superior therapeutic agents to Abiraterone and Enzalutamide are required to treat CRPC.
- AKR1C3 synthesizes potent ligands for the androgen receptor locally.
- AKR1C3 is upregulated by androgen deprivation in CRPC.
- Structurally diverse, potent and selective AKR1C3 inhibitors have been developed.
- AKR1C3 inhibitors need to be tested in xenograft models and taken into preclinical development.